SIRT6 and metabolic dysfunction-associated steatotic liver disease: USP10 can interact with Sirt6 and inhibit its ubiquitination and degradation to inhibit hepatic steatosis and inflammation.343 USP14 expression has been revised upwards in the livers of HFD, db/db mice and NAFLD patients and plays an indispensable role in hepatosteatosis via stabilization of FASN.344 Moreover, USP14 deubiquitinates HIF1-α to maintain its stability in hepatocellular carcinoma.345 The deubiquitinase cylindromatosis (CYLD) interacts with TAK1 and removes its K63-linked polyubiquitin chain to mitigate NASH.346